| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
2 companies
Morabito Christopher serves as a Chief Medical Officer at FULC and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 3 sells. Those positions are worth an estimated $10K at current prices.
Historically, Morabito Christopher's trades have earned a middling insider score of 61/100 across 4 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +20.7%.
The biggest single holding is FULC (~$10K) as Chief Medical Officer. Net of sales, the recent Form 4 record there shows accumulation of 1,100 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | ATXS Astria Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 10,000 | $13.59 | $135,939.00 | -100% | -31.5% | -60.0% | |
| Jan 29, 2024 | ATXS Astria Therapeutics, Inc. | Chief Medical Officer | Sale+OE | 10,000 | $11.14 | $111,364.40 | -100% | -24.3% | -38.0% | |
| Jun 28, 2021 | FULC Fulcrum Therapeutics, Inc. | Chief Medical Officer | Buy | 1,100 | $9.16 | $10,076.00 | New | +202.6% | -46.2% |